Stay updated on SubQ Lirentelimab Bioavailability in Healthy Adults Clinical Trial
Sign up to get notified when there's something new on the SubQ Lirentelimab Bioavailability in Healthy Adults Clinical Trial page.

Latest updates to the SubQ Lirentelimab Bioavailability in Healthy Adults Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now shows Revision: v3.6.4, replacing the previous Revision: v3.6.3, signaling an update to the page's revision.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, signaling a minor platform update. No study content or critical information appears to be altered.SummaryDifference0.1%

- Check40 days agoChange DetectedThe page’s revision tag was updated from v3.6.0 to v3.6.2, indicating an updated version of the record was published. This metadata change does not modify the study details or outcomes shown on the page.SummaryDifference0.1%

- Check54 days agoChange DetectedThe study page now indicates that recruitment is closed ('No longer looking for participants'), altering how users view enrollment. It also adds guidance sections ('How to Read a Study Record', 'Common Questions', 'How to Join a Study') and updates the page revision to v3.6.0.SummaryDifference0.5%

- Check61 days agoChange DetectedRevision indicator in the page footer was updated from v3.5.4 to v3.5.5, representing a minor build update. The visible content and functionality remain unchanged.SummaryDifference0.1%

- Check83 days agoChange DetectedThe page now displays Revision: v3.5.4, indicating an updated release/version; the previous Revision: v3.5.3 was removed.SummaryDifference0.1%

Stay in the know with updates to SubQ Lirentelimab Bioavailability in Healthy Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Lirentelimab Bioavailability in Healthy Adults Clinical Trial page.